Emergent BioSolutions Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 14 →InsidersNo open-market buys. 7 insiders sold $1.4M, 8 of 13 sales on a 10b5-1 plan.→HoldersBlackRock 9.2%Dimensional Fund 6.0%State Street 5.7%→PeersClosest companies: REGN, SUPN, AXSM→
From the filings
Figures
- Revenue
- $770.2Mlast 12 months
- Net income
- −$176.8Mlast 12 months
- Operating cash flow
- $148.0Mlast 12 months
- Cash and equivalents
- $139.7Mat the last balance sheet
- Total debt
- $581.8Mat the last balance sheet
- Shares outstanding
- 51.3M shareson issue